Monoclonal antibody · developed by SAb Biotherapeutics
SAB-176 is named in the trial record as a single ascending dose study drug, studied in Influenza A H1N1 infection and PHA1A.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04850898 | Phase 2 | Influenza A H1N1 | Completed | SABS |
| NCT06435936 | Phase 1 | PHA1A | Unknown | SABS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Influenza A H1N1PHA1A
See SABS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SABS catalysts and pipeline →